NCT03842254

Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Northwestern University · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the effect of erythropoietin on the number and function of regulatory T cells in adults with autoimmune hepatitis. Participants will receive a single dose of erythropoietin, and then the investigators will collect blood at different time points for analysis of regulatory T cell number and function.

Detailed description

There is data from the laboratory that erythropoietin helps stimulate regulatory T cells, a type of immune cell which is thought to combat autoimmunity, but this study will look at whether it does the same thing in adults with autoimmune hepatitis.

Conditions

• Autoimmune Hepatitis

Interventions

Type	Name	Description
DRUG	Erythropoietin	Subcutaneous injection of erythropoietin 10,000 units

Timeline

• Start date: 2019-01-25
• Primary completion: 2021-02-18
• Completion: 2021-02-18
• First posted: 2019-02-15
• Last updated: 2021-03-04

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study